// App-Quantinova.ai

5043 : A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Ivan de Kouchkovsky

Principal Investigators

  • Arpit Rao

  • Benedito A. Carneiro

  • Li Zhang

  • Catriona Lewis

  • Audrey Phone

  • Eric Jay Small

  • Terence W. Friedlander

  • Lawrence Fong

  • Pamela Paris

  • Charles J. Ryan

  • Russell Zelig Szmulewitz

  • Rahul Raj Aggarwal

Medical Centers

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Vascular Biology Center, Division of Hematology, Oncology & Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

  • Brown University, Lifespan Cancer Institute, Providence, RI

  • University of California School of Medicine, Irvine, CA

  • University of California, San Francisco, CA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • The University of Chicago Medical Center, Chicago, IL

  • University of California, San Francisco, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Ribociclib

  • Prednisone

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02494921

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved